MDV3100

From ASCO: Enzalutamide (MDV-3100) Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event

The American Society of Clinical Oncologists (ASCO) has started their annual conference in Chicago. I am anticipating a number of interesting and important abstracts that will be directly relevant to those of us with advanced prostate cancer. Among the first release of information comes an announcement from Medivation Inc. and Astellas Pharma Inc. who have [...]

By Malecare|2012-06-02T12:08:12-04:00June 2nd, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), MDV3100, On The Horizon, Uncategorized|0 Comments

Important Additional Information About Early/Expanded Access to Enzalutamide (MDV-3100)

I now have some additional information about the Early/Expanded Access Program for Enzalutamide (MDV-3100)for men with advanced prostate cancer. Jan Manarite, who is a member of the Early Access Committee has provided the following information: From the Early/Expanded Access Committee - Now available in 10 states (see list below in this post) with additional states [...]

By Malecare|2017-10-19T10:51:07-04:00May 31st, 2012|Advanced Prostate Cancer,